Targeting allosteric scaffolding functions of Aurora kinase A in cancer

靶向癌症中极光激酶 A 的变构支架功能

基本信息

  • 批准号:
    10373096
  • 负责人:
  • 金额:
    $ 34.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-01 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Neuroblastoma is the most common solid tumor in infants. About 25% of patients have high-risk neuroblastoma, a devastating disease with poor prognosis and few treatment options. The primary driver of high-risk neuroblastoma is the oncogene MYCN, a MYC-family transcription factor that has no druggable pockets and has long eluded drug development efforts. Recently, the protein kinase Aurora A (AurA) was shown to bind to the N-Myc protein in neuroblastoma cells and interfere with its ubiquitination by the SCF ubiquitin ligase complex, preventing N-Myc from being degraded by the proteosome. Blocking complex formation between AurA and N-Myc results in rapid N-Myc degradation and cell death in neuroblastoma cell lines. The same AurA/N-Myc complex has now been shown to drive neuroendocrine prostate cancer (NEPC), and AurA also forms a similar complex with the closely- related c-Myc protein in liver cancer. These recent discoveries point to a new paradigm for targeting Myc- family transcription factors in cancer using inhibitors that trigger structural changes in AurA that block Myc protein binding and promote Myc degradation. Our lab has recently shown that most existing AurA inhibitors, including the current clinical candidate alisertib, do not have a strong enough allosteric effect on AurA to be effective at weakening N-Myc binding. In agreement with this, alisertib has inconsistent effects on N-Myc levels in cell lines, and has not performed well in ongoing clinical trials in neuroblastoma and NEPC. The weakness in our current understanding of how AurA binds to c-Myc and N-Myc and how these interactions are affected by inhibitors represents a major impediment to this therapeutic strategy for targeting Myc-driven cancers. The goal of this project is to provide the missing molecular picture of the interactions between AurA and Myc transcription factors and how they can be modulated by inhibitor binding. We plan to use new experimental tools and approaches to define how the binding of c-Myc and N-Myc alters the conformation (shape) and dynamics (protein motion) of AurA, and to delineate the specific structural changes an inhibitor must trigger to efficiently destabilize these complexes. We will a) define the structure of the AurA/Myc complexes at atomic resolution using x-ray crystallography, magnetic resonance spectroscopies and molecular modeling, b) determine how these interactions alter AurA conformation and dynamics by tracking key structural elements of the kinase in solution, c) correlate the effects of a large panel of kinase inhibitors on AurA conformation with their ability to alter the binding affinities of N-Myc and c-Myc, and d) test the efficiency of the strongest AurA allosteric modulators in a series of N-Myc- and c-Myc-dependent cancer cell lines including neuroblastoma, NEPC and liver cancer cells. The insights will pave the way for the repurposing of existing kinase inhibitors and the development of new inhibitors as a new treatment modality for Myc-driven cancers.
摘要 神经母细胞瘤是婴儿最常见的实体瘤。大约25%的患者有高风险 神经母细胞瘤是一种预后不良且治疗选择很少的毁灭性疾病。的主要驱动力 高危神经母细胞瘤是癌基因MYCN,一种MYC家族转录因子, 口袋里,并长期逃避药物开发的努力。 最近,蛋白激酶Aurora A(AurA)被证明与神经母细胞瘤中的N-Myc蛋白结合 细胞,并通过SCF泛素连接酶复合物干扰其泛素化,阻止N-Myc被 被蛋白体降解阻断AurA和N-Myc之间的复合物形成导致快速的N-Myc 神经母细胞瘤细胞系中的降解和细胞死亡。同样的AurA/N-Myc复合物现在已经被证明 驱动神经内分泌前列腺癌(NEPC),而AurA也形成了一个类似的复合物, 相关c-Myc蛋白在肝癌中的表达。这些最近的发现指出了靶向Myc的新范例, 家族转录因子在癌症中使用抑制剂,触发AurA的结构变化, Myc蛋白结合并促进Myc降解。 我们的实验室最近表明,大多数现有的AurA抑制剂,包括目前的临床候选药物, alisertib对AurA没有足够强的变构作用,不能有效削弱N-Myc结合。在 与此一致,alisertib对细胞系中N-Myc水平的影响不一致,并且表现不佳 正在进行的神经母细胞瘤和NEPC的临床试验。我们目前对极光如何 与c-Myc和N-Myc结合,这些相互作用如何受到抑制剂的影响是一个主要障碍 这种针对Myc驱动的癌症的治疗策略。 这个项目的目标是提供缺失的分子之间的相互作用的图片 AurA和Myc转录因子以及它们如何通过抑制剂结合来调节。我们计划使用 新的实验工具和方法,以确定如何结合的c-Myc和N-Myc改变构象 AurA的形状和动力学(蛋白质运动),并描绘抑制剂的特定结构变化 必须触发以有效地破坏这些复合体的稳定性。我们将a)定义AurA/Myc的结构 使用X射线晶体学、磁共振光谱学和分子光谱学 建模,B)通过跟踪关键结构确定这些相互作用如何改变AurA构象和动力学 c)将一大组激酶抑制剂对AurA的影响关联起来 d)测试它们的构象与它们改变N-Myc和c-Myc的结合亲和力的能力,和 在一系列N-Myc和c-Myc依赖性癌细胞系中最强的AurA变构调节剂, 神经母细胞瘤、NEPC和肝癌细胞。这些见解将为重新利用现有的 激酶抑制剂和开发新的抑制剂作为Myc驱动的癌症的新治疗方式。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nicholas Mark Levinson其他文献

Nicholas Mark Levinson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nicholas Mark Levinson', 18)}}的其他基金

A transformative drug discovery platform for allosteric kinase inhibitors
变构激酶抑制剂的变革性药物发现平台
  • 批准号:
    10595089
  • 财政年份:
    2021
  • 资助金额:
    $ 34.75万
  • 项目类别:
A transformative drug discovery platform for allosteric kinase inhibitors
变构激酶抑制剂的变革性药物发现平台
  • 批准号:
    10097782
  • 财政年份:
    2021
  • 资助金额:
    $ 34.75万
  • 项目类别:
Targeting allosteric scaffolding functions of Aurora kinase A in cancer
靶向癌症中极光激酶 A 的变构支架功能
  • 批准号:
    10210065
  • 财政年份:
    2021
  • 资助金额:
    $ 34.75万
  • 项目类别:
Targeting allosteric scaffolding functions of Aurora kinase A in cancer
靶向癌症中极光激酶 A 的变构支架功能
  • 批准号:
    10593935
  • 财政年份:
    2021
  • 资助金额:
    $ 34.75万
  • 项目类别:
A transformative drug discovery platform for allosteric kinase inhibitors
变构激酶抑制剂的变革性药物发现平台
  • 批准号:
    10360449
  • 财政年份:
    2021
  • 资助金额:
    $ 34.75万
  • 项目类别:
Time-resolved FRET-based allostery sensors for any protein kinase drug target
适用于任何蛋白激酶药物靶标的时间分辨 FRET 变构传感器
  • 批准号:
    9887709
  • 财政年份:
    2020
  • 资助金额:
    $ 34.75万
  • 项目类别:
Time-resolved FRET-based allostery sensors for any protein kinase drug target
适用于任何蛋白激酶药物靶标的时间分辨 FRET 变构传感器
  • 批准号:
    10348717
  • 财政年份:
    2020
  • 资助金额:
    $ 34.75万
  • 项目类别:
Decoding the dynamic mechanism of allosteric activation in the cyclin-dependent kinase Cdk2
解读细胞周期蛋白依赖性激酶 Cdk2 变构激活的动态机制
  • 批准号:
    10321568
  • 财政年份:
    2018
  • 资助金额:
    $ 34.75万
  • 项目类别:
Kinome-Wide Spectroscopic Study of Drug Binding Site Electrostatics
药物结合位点静电的全激酶组光谱研究
  • 批准号:
    8351780
  • 财政年份:
    2012
  • 资助金额:
    $ 34.75万
  • 项目类别:
Kinome-Wide Spectroscopic Study of Drug Binding Site Electrostatics
药物结合位点静电的全激酶组光谱研究
  • 批准号:
    8973668
  • 财政年份:
    2012
  • 资助金额:
    $ 34.75万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.75万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 34.75万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 34.75万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.75万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 34.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.75万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 34.75万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 34.75万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 34.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 34.75万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了